Document Detail


Plasminogen activator inhibitor-1 in patients with atrial arrhythmias during acute myocardial infarction, treated with streptokinase.
MedLine Citation:
PMID:  12441914     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Atrial arrhythmias (AA), especially atrial fibrillation (AF), during acute myocardial infarction (AMI) are often associated with increased mortality and heart failure. Impaired fibrinolysis with elevated plasminogen activator inhibitor-1 (PAI-1) activity is associated with resistance to fibrinolytic therapy in AMI patients, but it is also found in patients with AF. Our aim was a prospective study of the role of pre-treatment PAI-1 levels for the presence of AA in AMI patients and the influence of AA on in-hospital mortality. In 116 AMI patients, treated with streptokinase, pre-treatment PAI-1 levels were estimated by the chromogenic method (normal levels, 0.3-3.5 U/ml) and in-hospital AA were assessed as atrial fibrillation, flutter and/or tachycardias. Between patients with and without AA, a significant difference was observed in mean pre-treatment PAI-1 levels, in several in-hospital complications and mortality (24 versus 4.4%; P < 0.01; odds ratio, 6.45; 95% confidence interval, 1.66-25.0). The PAI-1 level > 7 U/ml was the most significant independent pre-treatment risk factor for AA (P < 0.05; odds ratio, 3.5; 95% confidence interval, 1.15-10.6). We conclude that AA were a significant risk for in-hospital mortality of AMI patients, treated with streptokinase. A pre-treatment PAI-1 level > 7 U/ml was the most significant pre-treatment risk for AA in these patients.
Authors:
A Sinkovic
Related Documents :
19418394 - Is there an advantage to be gained from adding digital image cytometry of brush cytolog...
3029434 - Endocrine and exocrine profiles of men with testicular tumors before orchiectomy.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis     Volume:  13     ISSN:  0957-5235     ISO Abbreviation:  Blood Coagul. Fibrinolysis     Publication Date:  2002 Dec 
Date Detail:
Created Date:  2002-11-20     Completed Date:  2003-10-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9102551     Medline TA:  Blood Coagul Fibrinolysis     Country:  England    
Other Details:
Languages:  eng     Pagination:  741-7     Citation Subset:  IM    
Affiliation:
Department for Internal Intensive Medicine, General Hospital Maribor, Slovenia. andreja.sinkovic@guest.arnes.si
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Arrhythmias, Cardiac / blood*,  diagnosis,  etiology
Atrial Fibrillation / blood,  diagnosis,  etiology
Drug Therapy, Combination
Electrocardiography
Female
Heart Atria / physiopathology
Hospital Mortality
Humans
Male
Middle Aged
Myocardial Infarction / blood,  complications,  drug therapy*
Plasminogen Activator Inhibitor 1 / blood*
Predictive Value of Tests
Prospective Studies
Streptokinase / therapeutic use*
Chemical
Reg. No./Substance:
0/Plasminogen Activator Inhibitor 1; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Levels of vitamin K-dependent procoagulant and anticoagulant proteins in over-anticoagulated patient...
Next Document:  Superior venocaval obstruction secondary to central venous catheter-related thromboses in two patien...